Cardiovascular – Renal Drugs : Antiarrhythmics
ORYTM1 “Rytmonorm FC tablet” 150 mg/tab
適應症：心室性心搏過速、上心室性心搏過速、W-P-W症候群。
Usual dose:
Atrial fibrillation and flutter: PO
Adult: initial, 150 mg q8h, increase at 3-4 day intervals to 225-300 mg q8h.
Cardiac dysrhythmia: PO
Pediatric: initial, 200-300 mg/m2/24 h (divided in 3-4 equal doses) or 8-10 mg/kg/24 h (divided in 3-4 equal doses); titration, increase in 100 mg/m2/24 h or 2 mg/kg/24 h increments at 2-3 day intervals; max. 600 mg/m2/24 h or 20 mg/kg/24 h.
Paroxysmal atrial fibrillation, P’ts without structural heart disease: PO
Adult: titration, increase at 3-4 day intervals to 225-300 mg q8h.
Paroxysmal supraventricular tachycardia: PO
Adult: initial, 150 mg q8h; titration, increase at 3-4 day intervals to 225-300 mg q8h.
Ventricular arrhythmia: PO
Adult: initial, 150 mg q8h; titration, increase at 3-4 day intervals to 225-300 mg q8h
Dose adjustment:
Hepatic failure: 20-30% of immediate-release dose given to p’ts with normal liver function.
Geriatric: titration, increase dose more gradually.
Contraindication:
Bradycardia, bronchospastic disorders, cardiogenic shock, electrolyte imbalances, uncontrolled congestive heart failure, severe hypotension, sinoatrial, atrioventricular, and intraventricular disorders of impulse generation and/or conduction (eg, sick sinus syndrome, AV block) in the absence of an artificial pacemaker.
Adverse effect:
Common: rash, constipation, diarrhea, loss of appetite, nausea and vomiting, taste sense altered, ataxia, dizziness, headache, insomnia, tremor, blurred vision, anxiety, fatigue.
Serious: angina, bradyarrhythmia, cardiac dysrhythmia, chest pain, heart block, heart failure, hypotension, palpitations, disease of hematopoietic system, hepatotoxicity, systemic lupus erythematosus, bronchospasm.